Immutep Limited (ASX: IMM) - ETF Exposure
- Current share price for IMM : $0.034
Immutep Ltd (IMM) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a Phase III, clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG 3) related immunotherapies for cancer and autoimmune disease.
IMM General Information +
| ASX Code | IMM |
| Website | http://www.immutep.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 50 |
| IMM Share Price | $0.034 |
| Day High | $0.035 |
| Day Low | $0.033 |
| Last Close | $0.034 |
| IMM Share Price Movement | - ( No change ) |
Prices as at 16:40, 30 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Already own an Australian ETF? You may already have meaningful exposure to IMM
Immutep Limited (IMM) is held across 8 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when IMM moves, funds like IMPQ, ISO, SSO and VAS that hold it can move with it.
For more concentrated exposure, ETFs such as IMPQ (eInvest Better Future (Managed Fund)) allocate about 0.5% to IMM , while the average exposure across all 8 ETFs that hold it is around 0.1% .
Top ETF holdings
- eInvest Better Future (Managed Fund) (IMPQ) ~ 0.5%
- iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) ~ 0%
- State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) ~ 0%
- Vanguard Australian Shares Index ETF (VAS) ~ 0%
Last updated: ETF data and holdings as at 29 September 2026
Own IMM directly or through an ETF?
How does holding Immutep Limited (IMM) shares directly compare to ETFs that include it?
|
IMM Direct
|
IMPQ
ASX |
ISO
ASX |
SSO
ASX |
VAS
ASX |
|
|---|---|---|---|---|---|
| Holdings | 1 company | 41 holdings | 218 holdings | 218 holdings | 331 holdings |
| IMM Weight | 100% | 0.5% | 0% | 0% | 0% |
| Diversification | Single Stock | Broad | Broad | Broad | Broad |
| Annual Cost | Brokerage only | 0.89% p.a. | 0.55% p.a. | 0.5% p.a. | 0.07% p.a. |
| Approx. Yield | 0% | 2.24% | 4.34% | 9.37% | 4.13% |
| Star Ratings | - |  |
|
|
|
Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not IMM's direct yield. Annual cost uses each ETF's MER.
IMM Exposure on $10,000 investment
How a $10,000 investment in Immutep Limited (IMM) one week ago compares with ETFs that hold it.
| Security | Investment type | Current price | 7-day price movement | Dollar change | Value today |
|---|---|---|---|---|---|
| Immutep Limited (IMM) | Direct share | $0.034 | -17.07% | -$1,707 | $8,293 |
| eInvest Better Future (Managed Fund) (IMPQ) | Equity - Australia Small/Mid Cap | $4.020 | -1.47% | -$147 | $9,853 |
| iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) | Equity - Australia Small/Mid Cap | $5.030 | -1.18% | -$118 | $9,882 |
| State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) | Equity - Australia Small/Mid Cap | $14.320 | -2.32% | -$232 | $9,768 |
| Vanguard Australian Shares Index ETF (VAS) | Equity - Australia | $110.120 | 0.31% | +$31 | $10,031 |
Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.
Immutep Limited (IMM) ETFs
8 ETFs hold Immutep Limited (IMM).
| ETF | IMM Weight | MER | Yield |
|---|---|---|---|
| eInvest Better Future (Managed Fund) (IMPQ) | 0.5% | 0.89% | 2.24% |
| iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) | 0% | 0.55% | 4.34% |
| State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) | 0% | 0.5% | 9.37% |
| Vanguard Australian Shares Index ETF (VAS) | 0% | 0.07% | 4.13% |
Immutep Limited (IMM) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Immutep Limited (IMM) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Immutep Limited (IMM) price-sensitive announcements
IMM - Immutep Quarterly Activities Report and Appendix 4C
Immutep Limited, a biotechnology company developing novel immunotherapies for cancer and a
Immutep Limited (IMM)
30 Jul 2026 | 8:24 AM
30 Jul 2026 | 8:24 AM
IMM - TACTI-004 Update & Positive Mature Data from INSIGHT-003
Immutep Limited announced significant advancements in their clinical trials for 1st line n
Immutep Limited (IMM)
13 Jul 2026 | 9:38 AM
13 Jul 2026 | 9:38 AM
IMM - Immutep Quarterly Activities Report and Appendix 4C
Immutep Limited reported its quarterly activities for the period ending 31 March 2026. The
Immutep Limited (IMM)
30 Apr 2026 | 9:01 AM
30 Apr 2026 | 9:01 AM
IMM - Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma
Immutep Limited has announced that the FDA has granted Orphan Drug Designation (ODD) for e
Immutep Limited (IMM)
15 Apr 2026 | 9:27 AM
15 Apr 2026 | 9:27 AM
Immutep Limited (IMM) Recent ASX Announcements
IMM Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2028F | C2 | -$3.60 | 30.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2027F | C2 | -$2.80 | -46.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2026A | -$76.21 | -$5.20 | 22.80% | 0.00 | 0.00 | 0.00% | 0.0% |
IMM Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 A | 2027 F | 2028 F | 2026 A | 2027 F | 2028 F | 2026 A | 2027 F | 2028 F | ||
| CSL Limited (CSL) | $87,296M | 0.7309 | -0.4430 | 0.0545 | 11.2697 | 20.2322 | 19.1858 | 2.34% | 2.29% | 2.36% |
| Immutep Limited (IMM) | $50M | 0.2275 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Mesoblast Limited (MSB) | $2,649M | -0.4380 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 323.8095 | 0.00% | 0.00% | 0.00% |
| PYC Therapeutics Limited (PYC) | $2,705M | -0.3971 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $5,469M | -1.3893 | 0.0000 | -0.2781 | 0.0000 | 177.5938 | 246.0245 | 0.00% | 0.00% | 0.00% |
IMM Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 0.81 | 0.00 |
| Market | 0.34 | 13.60 | 1.11 | 0.74 |
| Sector | 0.65 | 30.70 | 2.65 | 1.43 |
IMM Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Marc Voigt | Chief Financial Officer, Chief Executive Officer, Executive Director | 9 Jul 2014 |
| Professor Frederic Triebel | Executive Director | 13 Sep 2022 |
| Dr Russell J Howard | Non-Executive Chairman, Non-Executive Director | 8 May 2013 |
| Mr Pete A Meyers | Non-Executive Deputy Chairman, Non-Executive Director | 12 Feb 2014 |
| Ms Lis (Elisabeth) Boyce | Non-Executive Director | 11 Apr 2023 |
Immutep Limited (IMM) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 18 Sep 2024 | VOIGT, Marc | Buy | Indirect Shares | 29,500 | $0.340 | $10,030.000 |
| 16 Mar 2020 | CHAMBERLAIN, Grant | Buy | Indirect Shares | 360,623 | $0.277 | $99,755.740 |
| 6 Aug 2019 | CHAMBERLAIN, Grant | Issued | Indirect Shares | 401,635 | $0.021 | $8,434.335 |
See all changes in directors' interest & trades for Immutep Limited (IMM) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
IMM Management
| Name | Position |
|---|---|
| Deanne Miller | Chief Operating Officer,Company Secretary,General Counsel |
| Christian Mueller | Other Corporate Officer |
| Stephan Winckels | Other Corporate Officer |
IMM Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Immutep Limited (IMM). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 326,740,329 (22.17%) | The Bank of New York Mellon Corporation |
IMM Calendar of Events
| Date | Event |
|---|---|
| 30 August 2027 | Report (Annual) |
| 30 August 2027 | Report (Prelim) |
| 24 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
